Cara Therapeutics (NASDAQ:CARA) Now Covered by StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a research report issued on Sunday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Cara Therapeutics Price Performance

Shares of CARA stock opened at $0.27 on Friday. The stock has a 50-day simple moving average of $0.30 and a 200 day simple moving average of $0.45. Cara Therapeutics has a fifty-two week low of $0.24 and a fifty-two week high of $1.40. The stock has a market capitalization of $14.52 million, a P/E ratio of -0.12 and a beta of 0.70.

Cara Therapeutics (NASDAQ:CARA) last released its quarterly earnings results on Wednesday, August 14th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.10). Cara Therapeutics had a negative net margin of 1,010.20% and a negative return on equity of 241.31%. The company had revenue of $0.99 million during the quarter, compared to analyst estimates of $1.26 million. On average, sell-side analysts anticipate that Cara Therapeutics will post -1.24 earnings per share for the current year.

Hedge Funds Weigh In On Cara Therapeutics

An institutional investor recently raised its position in Cara Therapeutics stock. Disciplined Growth Investors Inc. MN lifted its stake in Cara Therapeutics, Inc. (NASDAQ:CARA) by 6.6% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,935,718 shares of the biopharmaceutical company’s stock after purchasing an additional 120,660 shares during the quarter. Disciplined Growth Investors Inc. MN owned 3.54% of Cara Therapeutics worth $499,000 as of its most recent filing with the Securities & Exchange Commission. 44.66% of the stock is currently owned by hedge funds and other institutional investors.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.